Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30

Barclays analyst Christopher Pasquale has initiated coverage on PROCEPT BioRobotics (NASDAQ: PRCT) with an Overweight rating. The firm has set a price target of $30 for the company's stock.